Diflunisal

Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.

Product Specifications

CAS Number

[22494-42-4]

Product Name Alternative

MK-647

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H361

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Diflunisal.html

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(C2=CC=C(F)C=C2F)=CC=C1O)O

Molecular Formula

C13H8F2O3

Molecular Weight

250.20

Precautions

H302, H315, H319, H335, H361

References & Citations

[1]Lin JH, et al. Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther. 1985 Nov;235 (2) :402-6.|[2]Winter CA, et al. Analgesic activity of diflunisal [MK-647; 5- (2,4-difluorophenyl) salicylic acid] in rats with hyperalgesia induced by Freund's adjuvant. J Pharmacol Exp Ther. 1979 Dec;211 (3) :678-85.|[3]Cappon GD, et al. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68 (1) :47-56.